Shares of Integra LifeSciences Holdings Corp. (NASDAQ:IART) reached a new 52-week high on Thursday . The stock traded as high as $80.63 and last traded at $80.44, with a volume of 91,216 shares traded. The stock had previously closed at $79.26.

Several research firms have weighed in on IART. Zacks Investment Research raised shares of Integra LifeSciences Holdings Corp. from a “hold” rating to a “buy” rating and set a $79.00 price target for the company in a research note on Monday, May 2nd. Barclays PLC upped their price objective on shares of Integra LifeSciences Holdings Corp. from $70.00 to $74.00 and gave the company an “equal weight” rating in a research note on Thursday, April 28th. Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, April 28th. Jefferies Group reaffirmed a “buy” rating on shares of Integra LifeSciences Holdings Corp. in a research note on Thursday, April 28th. Finally, Lake Street Capital upped their price objective on shares of Integra LifeSciences Holdings Corp. from $57.00 to $75.00 and gave the company a “hold” rating in a research note on Thursday, April 28th. Two research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Integra LifeSciences Holdings Corp. currently has a consensus rating of “Buy” and an average price target of $79.00.

The stock has a 50-day moving average price of $75.85 and a 200-day moving average price of $67.54. The company’s market capitalization is $3.01 billion.

Integra LifeSciences Holdings Corp. (NASDAQ:IART) last posted its earnings results on Wednesday, April 27th. The company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The company had revenue of $236.80 million for the quarter, compared to analysts’ expectations of $230.66 million. The business’s revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the business posted $0.76 earnings per share. On average, analysts anticipate that Integra LifeSciences Holdings Corp. will post $3.44 EPS for the current year.

In related news, CFO Glenn Coleman sold 3,563 shares of the firm’s stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of $70.62, for a total transaction of $251,619.06. Following the completion of the transaction, the chief financial officer now directly owns 12,263 shares of the company’s stock, valued at $866,013.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Joseph Vinhais sold 972 shares of the firm’s stock in a transaction on Monday, May 9th. The shares were sold at an average price of $73.36, for a total transaction of $71,305.92. Following the transaction, the vice president now directly owns 4,311 shares of the company’s stock, valued at $316,254.96. The disclosure for this sale can be found here.

Other institutional investors have modified their holdings of the company. New York State Common Retirement Fund boosted its position in shares of Integra LifeSciences Holdings Corp. by 3.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,400 shares of the company’s stock worth $1,789,000 after buying an additional 1,000 shares during the last quarter. Comerica Bank boosted its position in shares of Integra LifeSciences Holdings Corp. by 1.4% in the fourth quarter. Comerica Bank now owns 29,922 shares of the company’s stock worth $1,965,000 after buying an additional 401 shares during the last quarter. GSA Capital Partners LLP boosted its position in shares of Integra LifeSciences Holdings Corp. by 160.4% in the fourth quarter. GSA Capital Partners LLP now owns 34,122 shares of the company’s stock worth $2,313,000 after buying an additional 21,020 shares during the last quarter. IronBridge Capital Management LP acquired a new position in shares of Integra LifeSciences Holdings Corp. during the fourth quarter worth approximately $2,992,000. Finally, Rhumbline Advisers boosted its position in shares of Integra LifeSciences Holdings Corp. by 6.6% in the fourth quarter. Rhumbline Advisers now owns 45,298 shares of the company’s stock worth $3,070,000 after buying an additional 2,820 shares during the last quarter.

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.